Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569594 | 0.88 | ALOX5AP (0.47) | ALDH1A1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL14557747 | 0.85 | NPSR1 (0.48) | ALDH1A1CHRNB2CHRNA4LTA4HNPSR1 | |
| SCHEMBL14557756 | 0.81 | DPP4 (0.47) | NPSR1IRAK4 | |
| SCHEMBL5150212 | 0.80 | ALOX5AP (0.50) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL5150218 | 0.80 | ALOX5AP (0.50) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL14557753 | 0.80 | CHRNB4 (0.45) | ALDH1A1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL14557802 | 0.77 | DPP4 (0.47) | NPSR1IRAK4 | |
| SCHEMBL14557792 | 0.76 | DPP4 (0.41) | LTA4HIRAK4 | |
| SCHEMBL14557820 | 0.76 | DPP4 (0.46) | RAB9A | |
| SCHEMBL14557796 | 0.76 | DPP4 (0.48) | NPSR1IRAK4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ALDH1A1 120/4885CHRNB4 1075/4885CHRNA3 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.